A. Serretti, R. Zanardi, E. Galbusera, C. Cusin, D. Rossini, E. Lattuada, R. Lilli, C. Lorenzi, B. Corradi, L. Mandelli, E. Pisati, L. Tentoni, C. Facchinetti, M. Catalano, E. Smeraldi - Vol. 7, Settembre 2001, num.3
Testo Immagini Bibliografia Summary Riassunto Indice
Genetica della risposta antidepressiva nei Disturbi
dell’Umore
Genetics of the response to antidepressants
in Mood Disorders
1 Eaton WW, Anthony JC, Gallo J, Cai GJ, Tien A, Romanoski A, et al. Natural History of Diagnostic Interview Schedule Dsm-IV Major Depression – the Baltimore Epidemiologic Catchment Area Follow-Up. Archives of General Psychiatry 1997;54:993-9.
2 Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Archives of General Psychiatry 1991;48:1075-81.
3 Dohrenwend BP, Levav I, Shrout PE, Schwartz S, Naveh G, Link BG, et al. Socioeconomic status and psychiatric disorders: the causation-selection issue. Science 1992;255:946-52.
4 Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. American Journal of Psychiatry 1996;153:1411-7.
5 Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. Jama 1992;267:1478-83.
6 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington DC: American Psychiatric Association, 1994.
7 Anonymous. Practice guideline for major depressive disorder in adults. American Psychiatric Association. American Journal of Psychiatry 1993;150:1-26.
8 Anonymous. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. American Journal of Psychiatry 2000;157:1-45.
9 Joyce PR, Paykel ES. Predictors of drug response in depression. Archives of General Psychiatry 1989;46:89-99.
10 Coryell W, Coppen A, Zeigler VE, Biggs JT. Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples. Psychological Medicine 1982;12:135-9.
11 Stassen HH, Angst J, Delinistula A. Onset of Improvement Under Fluoxetine and Moclobemide. European Psychiatry 1998;13:128-33.
12 Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 1984;41:782-6.
13 Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W. Use of pattern analysis to identify true drug response. A replication. Archives of General Psychiatry 1987;44:259-64.
14 Pare CMB, Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to antidepressant. Lancet 1962:1340-3.
15 Sederer LI. Depression. In: Sederer LI, ed. Inpatients psychiatry diagnosis and treatment. Baltimore: William & Wilkins 1986:20.
16 O’ Reilly RL, Bouge L, Singh FM. Pharmachogenetic response to antidepressant in a multicase family with affective disorder. Biological Psychiatry 1994;36:467-71.
17 Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press 1995:933-44.
18 Deakin JFW. The Role of Serotonin in Depression and Anxiety. European Psychiatry 1998;13:S57-S63.
19 Price LH, Charney DS, Delgado PL, Heninger GR. Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology 1990;100:3-12.
20 Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915-9.
21 Schloss P, Williams DC. The Serotonin Transporter – a Primary Target For Antidepressant Drugs. Journal of Psychopharmacology 1998;12:115-21.
22 Anonymous. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. American Journal of Psychiatry 1994;151:1-36.
23 Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 1993;90:2542-6.
24 Lesch K, Gross J, Franzek E, Wolozin B, Riederer P, Murphy D. Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biological Psychiatry 1995;37:215-23.
25 Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwin GM, et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996;347:731-3.
26 Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, et al. Allelic variation of human serotonin trasporter gene expression. Journal of Neurochemistry 1996;66:2621-4.
27 Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M. Polymorphism Within the Promoter of the Serotonin Transporter Gene and Antidepressant Efficacy of Fluvoxamine. Molecular Psychiatry 1998;3:508-11.
28 Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. Journal of Clinical Psychopharmacology 2000;20:105-7.
29 Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215-9.
30 Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression. Neuropsychopharmacology 2000;23:587-90.
31 Craig SP, Boularand S, Darmon MC, Mallet J, Craig IW. Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization. Cytogenetics & Cell Genetics 1991;56:157-9.
32 Nielsen DA, Jenkins GL, Stefanisko KM, Jefferson KK, Goldman D. Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Research. Molecular Brain Research 1997;45:145-8.
33 Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, et al. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. European Archives of Psychiatry & Clinical Neuroscience 1997;247:297-302.
34 Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Molecular Psychiatry (In press).
35 Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. submitted.
36 Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological Psychiatry (In press).
37 Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social & Clinical Psychology 1967;6:278-96.
38 Bech P, Malt U, Dencker S, Ahlfors U, Elgen K, Lewander T, et al. Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatrica Scandinavica 1993;87(Suppl. 372):37-40.
39 Bellini L, Gatti F, Gasperini M, Smeraldi E. A comparison between delusional and non-delusional depressives. Journal of Affective Disorders 1992;25:129-38.
40 Sobin CA, Sackeim H. Psychomotor symptoms of depression. American Journal of Psychiatry 1997;154:4-17.
41 Lucca A, Lucini V, Catalano M, Alfano M, Smeraldi E. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. Neuropsychobiology 1994;29:108-11.
42 Lahiri DK, Nurnberger JIJ. A rapid non-enzimatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acid Research 1991;19:5444.
43 Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Archives of General Psychiatry 1993;50:739-50.
44 Elkin I, Gibbons RD, Shea MT, Sotsky SM, Watkins JT, Pilkonis PA, et al. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Journal of Consulting & Clinical Psychology 1995;63:841-7.
45 Serretti A, Lattuada E, Zanardi R, Franchini L, Smeraldi E. Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry Research 2000;94:185-90.
46 Hedeker D, Gibbons RD. MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors. Computer Methods & Programs in Biomedicine 1996;49:229-52.
47 Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. Journal of Clinical Psychopharmacology 1998;18:435-40.
48 Horden A, Holt NF, Burt CG, Gordon WF. Amitriptyline in depressive states. British Journal of Psychiatry 1963;109:815-25.
49 Kantor SJ, Glassman AH. Delusional depression: natural history and response to treatment. British Journal of Psychiatry 1977;133:351-60.
50 Nelson JC, Bowers MB. Delusional unipolar depression: description and drug response. Archives of General Psychiatry 1978;35:1321-8.
51 Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. American Journal of Psychiatry 1981;138:328-33.
52 Meyers BS, Greenberg R. Late-life delusional depression. Journal of Affective Disorders 1986;11:133-7.
53 Howarth BG, Grace MG. Depression, drugs, and delusions. Archives of General Psychiatry 1985;42:1145-7.
54 Kahn RS, Davis KL. New developments in dopamine and schizofrenia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven press 1995:1193-203.
55 Glassman AH, Roose SP. Delusional Depression. Archives of General Psychiatry 1981;38:424-7.
56 Frances A, Brown RP, Kocsis JH, Mann JJ. Psichotic depression: a separate entity? American Journal of Psychiatry 1981;138:831-3.
57 Jeste DV, Heaton SC, Paulsen JS, Ercoli L, Harris J, Heaton RK. Clinical and neuropsychological comparison of psychotic depression with nonpsychotic depression and schizophrenia. American Journal of Psychiatry 1996;153:490-6.
58 Breslau N, Meltzer HY. Validity of subtyping psychotic depression: examination of phenomenology and demographic characteristics. American Journal of Psychiatry 1988;145:35-40.
59 Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? American Journal of Psychiatry 1992;149:733-45.
60 Lattuada E, Serretti A, Cusin C, Gasperini M, Macciardi F, Smeraldi E. Symptomatologic analysis of psychotic and non-psychotic depression. Journal of Affective Disorders 1999;54:183-7.
61 Serretti A, Lattuada E, Cusin C, Gasperini M, Smeraldi E. Clinical and demographical features of psychotic and nonpsychotic depression. Comprehensive Psychiatry 1999;40:358-62.
62 Goodwin F, Jamison K. Manic-depressive illness. New York: Oxford University Press 1990.
63 Carroll KM, Nich C, Rounsaville BJ. Variability in treatment-seeking cocaine abusers: implications for clinical pharmacotherapy trials. NIDA Res Monogr 1997;175:137-57.
64 Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of Clinical Psychopharmacology 1995;15:217-22.
65 Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry 1994;51:248-51.
66 Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d’Experimentation Psychopharmacologique. American Journal of Psychiatry 1998;155:1346-51.
67 Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-7.
68 Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M, Smeraldi E, et al. How long should Pindolol be associated with Paroxetine to improve the antidepressant response? Journal of Clinical Psychopharmacology 1997;17:446-50.
69 Zanardi R, Franchini L, Gasperini M, Lucca L, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. Journal of Clinical Psychopharmacology 1998;18:441-6.
70 Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biological Psychiatry 1999;45:1170-7.
71 Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Archives of General Psychiatry 1999;375-9.
72 Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol augmentation of treatment-resistant depressed patients. Journal of Clinical Psychiatry 1997;58:437-9.
73 Barbujani G, Sokal RR. Genetic population structure of Italy. I. Geographic patterns of gene frequencies. Human Biology 1991;63:253-72.
74 Fuciarelli M, Vienna A, Paba E, Bastianini A, Sansonetti B, Capucci E, et al. PI, GC, HP, and TF serum protein polymorphisms in Siena, Tuscany, Italy, with a review of data for Italy. American Journal of Human Biology 1997;9:629-46.
75 Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Molecular Psychiatry 1997;2:457-62.
76 Liu W, Gu N, Feng G, Zhang J, Li S, Bai S, et al. Association of VNTR region of the human serotonin transporter gene with bipolar disorder among the Han Chinese. Chung Hua I Hsueh I Chuan Hsueh Tsa Chih 1998;15:345-8.
77 Collier D, Stöber G, Li T, Heils A, Catalano M, Di Bella D, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Molecular Psychiatry 1996;1:453-60.
78 Collier DA, Arranz MJ, Sham P, Battersby S, Vallada H, Gill P, et al. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport 1996;7:1675-9.
79 Rees M, Norton N, Jones I, McCandless F, Scourfield J, Holmans P, et al. Association studies of bipolar disorder at the human serotonin transporter gene (hSERT; 5HTT). Molecular Psychiatry 1997;2:398-402.
80 Coyle N, Jones I, Robertson E, Lendon C, Craddock N. Variation at the serotonin transporter gene influences susceptibility to bipolar affective puerperal psychosis. Lancet 2000;356:1490-1.
81 Bellivier F, Laplanche JL, Leboyer M, Feingold J, Bottos C, Allilaire JF, et al. Serotonin transporter gene and manic depressive illness: an association study. Biological Psychiatry 1997;41:750-2.
82 Gutierrez B, Arranz MJ, Collier DA, Valles V, Guillamat R, Bertranpetit J, et al. Serotonin Transporter Gene and Risk For Bipolar Affective Disorder – an Association Study in a Spanish Population. Biological Psychiatry 1998;43:843-7.
83 Mendes de Oliveira JR, Otto PA, Vallada H, Lauriano V, Elkis H, Lafer B, et al. Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. American Journal of Medical Genetics 1998;81:225-7.
84 Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES, et al. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. American Journal of Medical Genetics 1998;81:58-63.
85 Hoehe MR, Wendel B, Grunewald I, Chiaroni P, Levy N, Morris-Rosendahl D, et al. Serotonin transporter (5-HTT) gene polymorphisms are not associated with susceptibility to mood disorders. American Journal of Medical Genetics 1998;81:1-3.
86 Esterling LE, Yoshikawa T, Turner G, Badner JA, Bengel D, Gershon ES, et al. Serotonin transporter (5-HTT) gene and bipolar affective disorder. American Journal of Medical Genetics 1998;81:37-40.
87 Oruc L, Verheyen GR, Furac I, Jakovljevic M, Ivezic S, Raeymaekers P, et al. Association analysis of the 5-HT2C receptor and 5-HT transporter genes in bipolar disorder. American Journal of Medical Genetics 1997;74:504-6.
88 Ewald H, Flint T, Degn B, Mors O, Kruse TA. A functional variant of the serotonin transporter gene in families with bipolar affective disorder. Journal of Affective Disorders 1998;48:135-44.
89 Kelsoe J, Remick R, Sadovnick A, Kristbjarnarson H, Flodman P, Spence M, et al. Genetic linkage study of bipolar disorder and the serotonin transporter. American Journal of Medical Genetics 1996;67:215-7.
90 Lenzinger E, Neumeister A, Praschak-Rieder N, Fuchs K, Gerhard E, Willeit M, et al. Behavioral effects of tryptophan depletion in seasonal affective disorder associated with the serotonin transporter gene? Psychiatry Research 1999;85:241-6.
91 Iqbal N, van Praag HM. The role of serotonin in schizophrenia. European Neuropsychopharmacology 1995;5:11-23.
92 Busatto GF, Kerwin RW. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. Journal of Psychopharmacology 1997;11:3-12.
93 Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research 1995;14:187-202.
94 Naylor L, Dean B, Opeskin K, Pavey G, Hill C, Keks N, et al. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. Journal of Neural Transmission – General Section 1996;103:749-57.
95 Dean B, Opeskin K, Pavey G, Naylor L, Hill C, Keks N, et al. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. Journal of Neurochemistry 1995;64:1197-202.
96 Mundo E, Walker M, Tims H, Macciardi F, Kennedy JL. Lack of linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and bipolar disorder. Am J Med Genet 2000;96:379-83.
97 Ospina-Duque J, Duque C, Carvajal-Carmona L, Ortiz-Barrientos D, Soto I, Pineda N, et al. An association study of bipolar mood disorder (type I) with the 5-HTTLPR serotonin transporter polymorphism in a human population isolate from colombia. Neurosci Lett 2000;292:199-202.
98 Saleem Q, Ganesh S, Vijaykumar M, Reddy YC, Brahmachari SK, Jain S. Association analysis of 5HT transporter gene in bipolar disorder in the Indian population. Am J Med Genet 2000;96:170-2.
99 Lesch K, Bengel D, Heils A, Sabol S, Greenberg B, Petri S, et al. Association of anxiety-related traits with a polymorphismin the serotonin transporter gene regulatory region. Science 1996;274:1527-30.
100 Jorm AF, Prior M, Sanson A, Smart D, Zhang Y, Easteal S. Association of a functional polymorphism of the serotonin transporter gene with anxiety-related temperament and behavior problems in children: a longitudinal study from infancy to the mid-teens. Molecular Psychiatry 2000;5:542-7.
101 Greenberg BD, Li Q, Lucas FR, Hu S, Sirota LA, Benjamin J, et al. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. Am J Med Genet 2000;96:202-16.
102 Gustavsson JP, Nothen MM, Jonsson EG, Neidt H, Forslund K, Rylander G, et al. No association between serotonin transporter gene polymorphisms and personality traits. American Journal of Medical Genetics 1999;88:430-6.
103 Kumakiri C, Kodama K, Shimizu E, Yamanouchi N, Okada S, Noda S, et al. Study of the association between the serotonin transporter gene regulatory region polymorphism and personality traits in a Japanese population. Neuroscience Letters 1999;263:205-7.
104 Katsuragi S, Kunugi H, Sano A, Tsutsumi T, Isogawa K, Nanko S, et al. Association between serotonin transporter gene polymorphism and anxiety-related traits. Biological Psychiatry 1999;45:368-70.
105 Murakami F, Shimomura T, Kotani K, Ikawa S, Nanba E, Adachi K. Anxiety traits associated with a polymorphism in the serotonin transporter gene regulatory region in the Japanese. J Hum Genet 1999;44:15-7.
106 Serretti A, Cusin C, Lattuada E, Di Bella D, Catalano M, Smeraldi E. Serotonin Transporter Gene (5-HTTLPR) is not Associated with Depressive Symptomatology in Mood Disorders. Molecular Psychiatry 1999;4:280-3.
107 Rosenthal N, Mazzanti C, Barnett R, Hardin T, Turner E, Lam G, et al. Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. Molecular Psychiatry 1998;3:175-7.
108 Ohara K, Nagai M, Suzuki Y, Ochiai M. Association between anxiety disorders and a functional polymorphism in the serotonin transporter gene. Psychiatry Research 1998;81:277-9.
109 Klauck SM, Poustka F, Benner A, Lesch KP, Poustka A. Serotonin transporter (5-HTT) gene variants associated with autism? Human Molecular Genetics 1997;6:2233-8.
110 Cook EH Jr., Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A, et al. Evidence of linkage between the serotonin transporter and autistic disorder. Molecular Psychiatry 1997;2:247-50.
111 Persico AM, Militerni R, Bravaccio C, Schneider C, Melmed R, Conciatori M, et al. Lack of association between serotonin transporter gene promoter variants and autistic disorder in two ethnically distinct samples. American Journal of Medical Genetics 2000;96:123-7.
112 Ohara K, Suzuki Y, Ochiai M, Tsukamoto T, Tani K. A variable-number-tandem-repeat of the serotonin transporter gene and anxiety disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1999;23:55-65.
113 Hamilton SP, Heiman GA, Haghighi F, Mick S, Klein DF, Hodge SE, et al. Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder. Psychiatric Genetics 1999;9:1-6.
114 Sander T, Harms H, Lesch KP, Dufeu P, Kuhn S, Hoehe M, et al. Association analysis of a regulatory variation of the serotonin transporter gene with severe alcohol dependence. Alcoholism, Clinical & Experimental Research 1997;21:1356-9.
115 Hammoumi S, Payen A, Favre JD, Balmes JL, Benard JY, Husson M, et al. Does the short variant of the serotonin transporter linked polymorphic region constitute a marker of alcohol dependence? Alcohol 1999;17:107-12.
116 Bellivier F, Szoke A, Henry C, Lacoste J, Bottos C, Nosten-Bertrand M, et al. Possible association between serotonin transporter gene polymorphism and violent suicidal behavior in mood disorders. Biological Psychiatry 2000;48:319-22.
117 Gorwood P, Batel P, Ades J, Hamon M, Boni C. Serotonin transporter gene polymorphisms, alcoholism, and suicidal behavior. Biological Psychiatry 2000;48:259-64.
118 Geijer T, Frisch A, Persson ML, Wasserman D, Rockah R, Michaelovsky E, et al. Search for association between suicide attempt and serotonergic polymorphisms. Psychiatric Genetics 2000;10:19-26.
119 Bligh-Glover W, Kolli TN, Shapiro-Kulnane L, Dilley GE, Friedman L, Balraj E, et al. The serotonin transporter in the midbrain of suicide victims with major depression. Biological Psychiatry 2000;47:1015-24.
120 Malhotra AK, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D. A Functional Serotonin Transporter (5-Htt) Polymorphism Is Associated With Psychosis in Neuroleptic-Free Schizophrenics. Molecular Psychiatry 1998;3:328-32.
121 Serretti A, Lattuada E, Catalano M, Smeraldi E. Serotonin transporter gene not associated with psychotic symptomatology of mood disorders. Psychiatry Research 1999;86:59-65.
122 Serretti A, Catalano M, Smeraldi E. Serotonin transporter gene is not associated with symptomatology of schizophrenia. Schizophrenia Research 1999;35:33-9.
123 Bonnet-Brilhault F, Laurent C, Thibaut F, Campion D, Chavand O, Samolyk D, et al. Serotonin transporter gene polymorphism and schizophrenia: an association study. Biological Psychiatry 1997;42:634-6.
124 Stober G, Jatzke S, Heils A, Jungkunz G, Fuchs E, Knapp M, et al. Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene. European Archives of Psychiatry & Clinical Neuroscience 1998;248:82-6.
125 Naylor L, Dean B, Pereira A, Mackinnon A, Kouzmenko A, Copolov D. No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. Molecular Medicine 1998;4:671-4.
126 Rao D, Jonsson E, Paus S, Ganguli R, Nothen M, Nimgaonkar V. Schizophrenia and the serotonin transporter gene. Psychiatric Genetics 1998;8:207-12.
127 Hranilovic D, Schwab SG, Jernej B, Knapp M, Lerer B, Albus M, et al. Serotonin transporter gene and schizophrenia: evidence for association/linkage disequilibrium in families with affected siblings. Molecular Psychiatry 2000;5:91-5.
128 Tsai SJ, Hong CJ, Yu YW, Lin CH, Song HL, Lai HC, et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophrenia Research 2000;44:177-81.
129 Billett EA, Richter MA, King N, Heils A, Lesch KP, Kennedy JL. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Molecular Psychiatry 1997;2:403-6.
130 Devor EJ, Magee HJ, Dill-Devor RM, Gabel J, Black DW. Serotonin transporter gene (5-HTT) polymorphisms and compulsive buying. American Journal of Medical Genetics 1999;88:123-5.
131 Hinney A, Barth N, Ziegler A, von Prittwitz S, Hamann A, Hennighausen K, et al. Serotonin transporter gene-linked polymorphic region: allele distributions in relationship to body weight and in anorexia nervosa. Life Sciences 1997;61:295-303.
132 Matsushita S, Muramatsu T, Kimura M, Shirakawa O, Mita T, Nakai T, et al. Serotonin transporter gene regulatory region polymorphism and panic disorder. Molecular Psychiatry 1997;2:390-2.
133 Tan EC, Yeo BKL, Ho BKW, Tay AHN, Tan CH. Evidence for an association between heroin dependence and a VNTR polymorphism at the serotonin transporter locus. Molecular Psychiatry 1999;4:215-7.
134 Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, et al. Association between the tryptophan hydroxylase gene and manic-depressive illness. Archives of General Psychiatry 1998;55:33-7.
135 Frisch A, Postilnick D, Rockah R, Michaelovsky E, Postilnick S, Birman E, et al. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Molecular Psychiatry 1999;4:389-92.
136 Rietschel M, Schorr A, Albus M, Franzek E, Kreiner R, Held T, et al. Association study of the tryptophan hydroxylase gene and bipolar affective disorder using family-based internal controls. Am J Med Genet 2000;96:310-1.
137 Han L, Nielsen DA, Rosenthal NE, Jefferson K, Kaye W, Murphy D, et al. No coding variant of tryptophan hydroxylase gene detected in seasonal affective disorder, obsessive-compulsive disorder, anorexia nervosa, and alcoholism. Biological Psychiatry 1999;45:615-9.
138 Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC. No association of the tryptophan hydroxylase gene with bipolar affective disorder, unipolar affective disorder, or suicidal behaviour in major affective disorder. American Journal of Medical Genetics 1998;81:245-7.
139 Tsai SJ, Hong CJ, Wang YC. Tryptophan hydroxylase gene polymorphism (A218C) and suicidal behaviors. Neuroreport 1999;10:3773-5.
140 Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Archives of General Psychiatry 1994;51:34-8.
141 Risch N. Linkage strategies for genetically complex traits: I. Multilocus models. American Journal of Medical Genetics 1990;46:222-8.
142 Comings D. Polygenic inheritance in psychiatric disorders. In: Blum K, Noble EP, eds. Handbook of Psychiatric Genetics. Boca Raton: CRC press 1997:235-60.